Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home
  • Log in
  • My Cart

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
Research Article

Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques

Dariusz K. Murakowski, View ORCID ProfileJohn P. Barton, View ORCID ProfileLauren Peter, Abishek Chandrashekar, Esther Bondzie, Ang Gao, Dan H. Barouch, and Arup K. Chakraborty
  1. aDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;
  2. bRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139;
  3. cInstitute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139;
  4. dCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215;
  5. eDepartment of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139;
  6. fDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139

See allHide authors and affiliations

PNAS February 2, 2021 118 (5) e2022496118; https://doi.org/10.1073/pnas.2022496118
Dariusz K. Murakowski
aDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;
bRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John P. Barton
bRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139;
cInstitute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John P. Barton
Lauren Peter
dCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lauren Peter
Abishek Chandrashekar
dCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Bondzie
dCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ang Gao
cInstitute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan H. Barouch
bRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139;
dCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dbarouch@bidmc.harvard.edu arupc@mit.edu
Arup K. Chakraborty
aDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;
bRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139;
cInstitute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139;
eDepartment of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139;
fDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dbarouch@bidmc.harvard.edu arupc@mit.edu
  1. Contributed by Arup K. Chakraborty, December 28, 2020 (sent for review November 2, 2020; reviewed by Julie McElrath and Martin Weigt)

  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Significance

HIV is a highly mutable pathogen that can mutate to evade vaccine-induced immune responses, thus negating the vaccine’s protective effects. If mutations that evade immune responses incur a fitness penalty for the virus, other mutations can evolve to partially compensate for fitness loss. Accounting for such effects, we designed a single long peptide immunogen comprised of parts of HIV proteins wherein mutations would be difficult to evolve without fitness penalties for the virus. This designed immunogen was expressed in adenovirus vectors, which are in clinical development (e.g., for COVID-19). Monkeys immunized with our vaccine exhibited strong T-cell responses directed toward regions contained in our immunogen. This suggests that further exploration of this vaccine for use in humans is warranted.

Abstract

An effective vaccine that can protect against HIV infection does not exist. A major reason why a vaccine is not available is the high mutability of the virus, which enables it to evolve mutations that can evade human immune responses. This challenge is exacerbated by the ability of the virus to evolve compensatory mutations that can partially restore the fitness cost of immune-evading mutations. Based on the fitness landscapes of HIV proteins that account for the effects of coupled mutations, we designed a single long peptide immunogen comprising parts of the HIV proteome wherein mutations are likely to be deleterious regardless of the sequence of the rest of the viral protein. This immunogen was then stably expressed in adenovirus vectors that are currently in clinical development. Macaques immunized with these vaccine constructs exhibited T-cell responses that were comparable in magnitude to animals immunized with adenovirus vectors with whole HIV protein inserts. Moreover, the T-cell responses in immunized macaques strongly targeted regions contained in our immunogen. These results suggest that further studies aimed toward using our vaccine construct for HIV prophylaxis and cure are warranted.

  • subunit vaccines
  • HIV
  • fitness landscape

Footnotes

  • ↵1To whom correspondence may be addressed. Email: dbarouch{at}bidmc.harvard.edu or arupc{at}mit.edu.
  • Author contributions: D.K.M., J.P.B., D.H.B., and A.K.C. designed research; D.K.M., J.P.B., L.P., A.C., and E.B. performed research; D.K.M., A.G., D.H.B., and A.K.C. analyzed data; and D.K.M., D.H.B., and A.K.C. wrote the paper.

  • Reviewers: J.M., Fred Hutchinson Cancer Research Center; and M.W., Sorbonne University.

  • Competing interest statement: The authors have filed an application for a patent on the immunogen.

  • This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2022496118/-/DCSupplemental.

Data Availability.

All study data are included in the article and/or SI Appendix.

Published under the PNAS license.

View Full Text

References

  1. ↵
    1. F. Barre-Sinoussi et al
    ., Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868–871 (1983).
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. M. Popovic,
    2. M. G. Sarngadharan,
    3. E. Read,
    4. R. C. Gallo
    , Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224, 497–500 (1984).
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. D. Sok,
    2. D. R. Burton
    , Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179–1188 (2018).
    OpenUrlCrossRefPubMed
  4. ↵
    1. P. D. Kwong,
    2. J. R. Mascola,
    3. G. J. Nabel
    , Broadly neutralizing antibodies and the search for an HIV-1 vaccine: The end of the beginning. Nat. Rev. Immunol. 13, 693–701 (2013).
    OpenUrlCrossRefPubMed
  5. ↵
    1. A. Escolano,
    2. P. Dosenovic,
    3. M. C. Nussenzweig
    , Progress toward active or passive HIV-1 vaccination. J. Exp. Med. 214, 3–16 (2017).
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. B. Walker,
    2. A. McMichael
    , The T-cell response to HIV. Cold Spring Harb. Perspect. Med. 2, 1–20 (2012).
    OpenUrlCrossRefPubMed
  7. ↵
    1. K. Deng et al
    ., Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381–385 (2015).
    OpenUrlCrossRefPubMed
  8. ↵
    1. D. R. Collins,
    2. G. D. Gaiha,
    3. B. D. Walker
    , CD8+ T cells in HIV control, cure and prevention. Nat. Rev. Immunol. 20, 471–482 (2020).
    OpenUrl
  9. ↵
    1. S. G. Hansen et al
    ., A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge. Sci. Transl. Med. 11, eaaw2607 (2019).
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. K. Früh,
    2. L. Picker
    , CD8+ T cell programming by cytomegalovirus vectors: Applications in prophylactic and therapeutic vaccination. Curr. Opin. Immunol. 47, 52–56 (2017).
    OpenUrlCrossRef
  11. ↵
    1. S. G. Hansen et al
    ., Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E. Science 351, 714–720 (2016).
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. J. P. Barton et al
    ., Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable. Nat. Commun. 7, 11660 (2016).
    OpenUrlCrossRefPubMed
  13. ↵
    1. A. J. McMichael,
    2. P. Borrow,
    3. G. D. Tomaras,
    4. N. Goonetilleke,
    5. B. F. Haynes
    , The immune response during acute HIV-1 infection: Clues for vaccine development. Nat. Rev. Immunol. 10, 11–23 (2010).
    OpenUrlCrossRefPubMed
  14. ↵
    1. R. E. Phillips et al
    ., Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354, 453–459 (1991).
    OpenUrlCrossRefPubMed
  15. ↵
    1. M. E. Feeney et al
    ., Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J. Virol. 78, 8927–8930 (2004).
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. B. Ondondo et al
    ., Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection. Mol. Ther. 24, 832–842 (2016).
    OpenUrlCrossRefPubMed
  17. ↵
    1. N. Borthwick et al
    ., Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol. Ther. 22, 464–475 (2014).
    OpenUrlCrossRefPubMed
  18. ↵
    1. S. Létourneau et al
    ., Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2, e984 (2007).
    OpenUrlCrossRefPubMed
  19. ↵
    1. N. Moyo et al
    ., Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA. Mol. Ther. Methods Clin. Dev. 12, 32–46 (2018).
    OpenUrl
  20. ↵
    1. H. Murakoshi et al
    ., CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication. Retrovirology 15, 46 (2018).
    OpenUrlCrossRefPubMed
  21. ↵
    1. N. Borthwick et al
    ., Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. PLoS One 12, e0176418 (2017).
    OpenUrl
  22. ↵
    1. J. Martinez-Picado et al
    ., Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80, 3617–3623 (2006).
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. M. A. Brockman et al
    ., Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J. Virol. 81, 12608–12618 (2007).
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. A. L. Ferguson et al
    ., Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity 38, 606–617 (2013).
    OpenUrlCrossRefPubMed
  25. ↵
    1. R. H. Y. Louie,
    2. K. J. Kaczorowski,
    3. J. P. Barton,
    4. A. K. Chakraborty,
    5. M. R. McKay
    , Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies. Proc. Natl. Acad. Sci. U.S.A. 115, E564–E573 (2018).
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. J. K. Mann et al
    ., The fitness landscape of HIV-1 gag: Advanced modeling approaches and validation of model predictions by in vitro testing. PLOS Comput. Biol. 10, e1003776 (2014).
    OpenUrlCrossRefPubMed
  27. ↵
    1. J. P. Barton et al
    ., Modelling and in vitro testing of the HIV-1 Nef fitness landscape. Virus Evol. 5, vez029 (2019).
    OpenUrl
  28. ↵
    1. V. Dahirel et al
    ., Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc. Natl. Acad. Sci. U.S.A. 108, 11530–11535 (2011).
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. T. C. Butler,
    2. J. P. Barton,
    3. M. Kardar,
    4. A. K. Chakraborty
    , Identification of drug resistance mutations in HIV from constraints on natural evolution. Phys. Rev. E 93, 022412 (2016).
    OpenUrl
  30. ↵
    1. K. Shekhar et al
    ., Spin models inferred from patient-derived viral sequence data faithfully describe HIV fitness landscapes. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 88, 062705 (2013).
    OpenUrlCrossRefPubMed
  31. ↵
    1. A. K. Chakraborty,
    2. J. P. Barton
    , Rational design of vaccine targets and strategies for HIV: A crossroad of statistical physics, biology, and medicine. Rep. Prog. Phys. 80, 032601 (2017).
    OpenUrl
  32. ↵
    1. G. D. Gaiha et al
    ., Structural topology defines protective CD8+ T cell epitopes in the HIV proteome. Science 364, 480–484 (2019).
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. S. F. Ahmed,
    2. A. A. Quadeer,
    3. D. Morales-Jimenez,
    4. M. R. McKay
    , Sub-dominant principal components inform new vaccine targets for HIV Gag. Bioinformatics 35, 3884–3889 (2019).
    OpenUrlCrossRef
  34. ↵
    1. D. H. Barouch,
    2. L. J. Picker
    , Novel vaccine vectors for HIV-1. Nat. Rev. Microbiol. 12, 765–771 (2014).
    OpenUrlCrossRefPubMed
  35. ↵
    1. D. H. Barouch et al
    ., Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89–93 (2012).
    OpenUrlCrossRefPubMed
  36. ↵
    1. E. N. Borducchi et al
    ., Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540, 284–287 (2016).
    OpenUrlCrossRefPubMed
  37. ↵
    1. D. H. Barouch et al
    ., Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392, 232–243 (2018).
    OpenUrlCrossRefPubMed
  38. ↵
    1. D. H. Barouch et al
    ., Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J. Infect. Dis. 207, 248–256 (2013).
    OpenUrlCrossRefPubMed
  39. ↵
    1. L. R. Baden et al
    ., First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J. Infect. Dis. 207, 240–247 (2013).
    OpenUrlCrossRefPubMed
  40. ↵
    1. L. R. Baden et al.; B003-IPCAVD004-HVTN091 Study Group
    , Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: A randomized trial. Ann. Intern. Med. 164, 313–322 (2016).
    OpenUrlCrossRefPubMed
  41. ↵
    1. L. R. Baden et al
    ., Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J. Infect. Dis. 211, 518–528 (2015).
    OpenUrlCrossRefPubMed
  42. ↵
    1. K. E. Stephenson et al
    ., First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS One 13, e0205139 (2018).
    OpenUrlPubMed
  43. ↵
    1. D. J. Colby et al
    ., Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat. Med. 26, 498–501 (2020).
    OpenUrlCrossRef
  44. ↵
    1. J. P. Barton,
    2. E. De Leonardis,
    3. A. Coucke,
    4. S. Cocco
    , ACE: Adaptive cluster expansion for maximum entropy graphical model inference. Bioinformatics 32, 3089–3097 (2016).
    OpenUrlCrossRefPubMed
  45. ↵
    1. D. H. Barouch et al
    ., Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16, 319–323 (2010).
    OpenUrlCrossRefPubMed
  46. ↵
    1. D. H. Barouch et al
    ., Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531–539 (2013).
    OpenUrlCrossRefPubMed
  47. ↵
    1. Los Alamos National Laboratory
    , Data from "Best-defined CTL/CD8+ epitope summary." HIV Molecular Immunology Database. https://www.hiv.lanl.gov/content/immunology/tables/optimal_ctl_summary.html. Accessed 2 January 2017.
  48. ↵
    1. P. Abbink et al
    ., Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654–4663 (2007).
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. D. M. Roberts et al
    ., Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239–243 (2006).
    OpenUrlCrossRefPubMed
  50. ↵
    1. M. Jia et al
    ., Preferential CTL targeting of Gag is associated with relative viral control in long-term surviving HIV-1 infected former plasma donors from China. Cell Res. 22, 903–914 (2012).
    OpenUrlCrossRefPubMed
  51. ↵
    1. S. G. Deeks,
    2. B. D. Walker
    , Human immunodeficiency virus controllers: Mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27, 406–416 (2007).
    OpenUrlCrossRefPubMed
  52. ↵
    1. The International HIV Controllers Study
    , The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551–1557 (2010).
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. C. Jiang et al
    ., Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 585, 261–267 (2020).
    OpenUrlCrossRefPubMed
  54. ↵
    1. B. Julg et al
    ., Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV 6, e259–e268 (2019).
    OpenUrl
  55. ↵
    1. A. Gao et al
    ., Predicting the immunogenicity of T cell epitopes: From HIV to SARS-CoV-2. bioRxiv [Preprint] (2020). https://doi.org/10.1101/2020.05.14.095885) (Accessed 25 October 2020).
  56. ↵
    1. F. Morcos et al
    ., Direct-coupling analysis of residue coevolution captures native contacts across many protein families. Proc. Natl. Acad. Sci. U.S.A. 108, E1293–E1301 (2011).
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. D. Frenkel,
    2. B. Smit
    , Understanding Molecular Simulation: From Algorithms to Applications (Elsevier, 2001).

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

Subscribers, for more details, please visit our Subscriptions FAQ.

Please click here to log into the PNAS submission website.

PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques
Dariusz K. Murakowski, John P. Barton, Lauren Peter, Abishek Chandrashekar, Esther Bondzie, Ang Gao, Dan H. Barouch, Arup K. Chakraborty
Proceedings of the National Academy of Sciences Feb 2021, 118 (5) e2022496118; DOI: 10.1073/pnas.2022496118

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques
Dariusz K. Murakowski, John P. Barton, Lauren Peter, Abishek Chandrashekar, Esther Bondzie, Ang Gao, Dan H. Barouch, Arup K. Chakraborty
Proceedings of the National Academy of Sciences Feb 2021, 118 (5) e2022496118; DOI: 10.1073/pnas.2022496118
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley

Article Classifications

  • Biological Sciences
  • Immunology and Inflammation
  • Physical Sciences
  • Biophysics and Computational Biology
Proceedings of the National Academy of Sciences: 118 (5)
Table of Contents

Submit

Sign up for Article Alerts

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Methods
    • Data Availability.
    • Acknowledgments
    • Footnotes
    • References
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Smoke emanates from Japan’s Fukushima nuclear power plant a few days after tsunami damage
Core Concept: Muography offers a new way to see inside a multitude of objects
Muons penetrate much further than X-rays, they do essentially zero damage, and they are provided for free by the cosmos.
Image credit: Science Source/Digital Globe.
Water from a faucet fills a glass.
News Feature: How “forever chemicals” might impair the immune system
Researchers are exploring whether these ubiquitous fluorinated molecules might worsen infections or hamper vaccine effectiveness.
Image credit: Shutterstock/Dmitry Naumov.
Venus flytrap captures a fly.
Journal Club: Venus flytrap mechanism could shed light on how plants sense touch
One protein seems to play a key role in touch sensitivity for flytraps and other meat-eating plants.
Image credit: Shutterstock/Kuttelvaserova Stuchelova.
Illustration of groups of people chatting
Exploring the length of human conversations
Adam Mastroianni and Daniel Gilbert explore why conversations almost never end when people want them to.
Listen
Past PodcastsSubscribe
Horse fossil
Mounted horseback riding in ancient China
A study uncovers early evidence of equestrianism in ancient China.
Image credit: Jian Ma.

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Special Feature Articles – Most Recent
  • List of Issues

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Subscribers
  • Librarians
  • Press
  • Cozzarelli Prize
  • Site Map
  • PNAS Updates
  • FAQs
  • Accessibility Statement
  • Rights & Permissions
  • About
  • Contact

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490